- Home
- CSTL
as 05-14-2025 1:34pm EST
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | FRIENDSWOOD |
| Market Cap: | 558.7M | IPO Year: | 2019 |
| Target Price: | $38.33 | AVG Volume (30 days): | 561.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.18 | EPS Growth: | N/A |
| 52 Week Low/High: | $15.70 - $35.84 | Next Earning Date: | 05-05-2025 |
| Revenue: | $347,083,000 | Revenue Growth: | 38.43% |
| Revenue Growth (this year): | -11.18% | Revenue Growth (next year): | 3.14% |
Stock Insider Trading Activity of Castle Biosciences Inc. (CSTL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Mar 26 '25 | Sell | $20.30 | 5,644 | $114,573.20 | 4,605 | |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Mar 7 '25 | Sell | $20.34 | 29,177 | $585,673.31 | 4,605 | |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Mar 4 '25 | Sell | $20.86 | 5,687 | $118,619.45 | 4,605 | |
| Stokes Frank | CSTL | Chief Financial Officer | Feb 20 '25 | Sell | $26.70 | 8,046 | $214,828.20 | 35,319 |
Latest Castle Biosciences Inc. News
CSTL Breaking Stock News: Dive into CSTL Ticker-Specific Updates for Smart Investing
GlobeNewswire
5 days ago
Real-World Study Confirms Long-Term Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with the DecisionDx-UM Class Result
Simply Wall St.
7 days ago
Castle Biosciences First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
GlobeNewswire
7 days ago
Castle Biosciences Celebrates Skin Cancer Awareness Month
Thomson Reuters StreetEvents
8 days ago
Q1 2025 Castle Biosciences Inc Earnings Call
GuruFocus.com
8 days ago
Castle Biosciences Inc (CSTL) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst ...
Zacks
9 days ago
Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates
GlobeNewswire
9 days ago
Castle Biosciences Reports First Quarter 2025 Results
GlobeNewswire
9 days ago
Castle Biosciences to Acquire Previse
Compare CSTL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CSTL Castle Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.